TESARO (TSRO) Misses Q3 EPS by 6c

TESARO (NASDAQ: TSRO) reported Q3 EPS of ($1.98), $0.06 worse than the analyst estimate of ($1.92). Revenue for the quarter came in at $3.73 million versus the consensus estimate of $4.39 million.

“We are very pleased to have submitted regulatory applications for niraparib in both the United States and in Europe for the maintenance treatment of patients with platinum-sensitive, recurrent ovarian cancer who are in response to platinum-based chemotherapy. Pre-launch activities are well underway in support of four potential product launches in 2017, including VARUBI® IV and niraparib in the U.S and VARUBI oral and niraparib in Europe,” said Lonnie Moulder, CEO of TESARO. “The recent ESMO 2016 Congress was very gratifying for TESARO, highlighted by the presentation of the landmark niraparib NOVA trial results during a Presidential Symposium by Dr. Mansoor Raza Mirza. We look forward to advancing our comprehensive ovarian cancer clinical program and expanding niraparib development into other tumor types in 2017.”

For earnings history and earnings-related data on TESARO (TSRO) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance
• The Hartford (HIG) Misses Q1 EPS by 13c